Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
|Articles|October 16, 2012
Twitter feed Psychiatric Times Coverage of HMP Global, LLC’s Psych Congress® Conference 2012
Listen
0:00 / 0:00
Key Takeaways
- Source material is derived from Psych Congress® presentations and then shaped into articles and interviews by Psychiatric Times editors and contributors.
- Independence is emphasized through clear statements of no affiliation, endorsement, or sponsorship by third parties.
Advertisement
The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at Psych Congress®, an annual conference produced by HMP Global, LLC. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by HMP Global, LLC. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of HMP Global, LLC.
Advertisement
Related to this article
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
3
Treating PTSD Among Veterans at Risk for Suicide
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5